anti-CD20 antibody-drug conjugate TRS005

{
  "id": "MLC-T-ONC-010285",
  "term": "anti-CD20 antibody-drug conjugate TRS005",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of an anti-CD20 monoclonal antibody conjugated via a valine-citrulline linker to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-CD20 ADC TRS005 targets and binds to CD20 on the surfaces of tumor B cells. Upon internalization and cleavage, MMAE is released. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD20-expressing tumor cells. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B-cell development. It is often overexpressed in B-cell malignancies.",
  "synonyms": [
    "anti-CD20 ADC TRS005",
    "anti-CD20/MMAE ADC TRS005",
    "ADC TRS005"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd20-antibody-drug-conjugate-trs005/"
}